A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators. The findings suggest new therapeutic strategies for a variety of cancer types.
Study Reveals Mechanism of Cancer Mutations and Implications for Treatment
A study by Weill Cornell Medicine reveals that a family of mutations found in 20% of human cancers alters gene accessibility to a regulatory protein, potentially leading to new cancer therapies. This research could influence cancer treatment approaches globally, including in Iran. The findings may have implications for healthcare advancements in the country.
👥 Key Players
📰 What Happened
A study by Weill Cornell Medicine has identified a family of mutations that affect gene accessibility in about 20% of human cancers, potentially leading to new cancer treatment strategies.
- The mutations change the accessibility of genes to a regulatory protein.
- The findings could influence cancer treatment approaches globally.
💡 Why It Matters
📚 Background
Cancer mutations play a critical role in the development and progression of various cancers, making research in this area vital for effective treatments.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%